生脉注射液联合化疗治疗晚期非小细胞肺癌的临床研究

目的:观察生脉注射液联合泰素加卡铂方案治疗晚期非小细胞肺癌的临床效果及其减毒作用。方法:将38例晚期非小细胞肺癌患者随机分为治疗组和对照组各19例。对照组第1天予泰素135 mg/m2,3 h静滴,卡铂AUC 5静滴,21 d为1个周期;治疗组予同一化疗方案并于化疗结束后第2天用生脉注射液60 m l加入50 g/L葡萄糖注射液500 m l静滴,每天1次,连用15 d。两个周期后按照WHO实体瘤近期客观疗效评定标准进行评价。结果:治疗组和对照组近期有效率分别为52.6%和47.4%;治疗组Karnorfsky评分增加6例,对照组增加3例;治疗组体质量明显增加,骨髓抑制发生率明显较对照组低。结论:生脉注射液能提高泰素加卡铂方案化疗患者的生存质量,减轻化疗后骨髓抑制。

Clinical Study on the Treatment of Advanced NSCLC with Shengmai Injection Combined with Chemotherapy

Objective: To observe the clinical efficiency and side effects of Shengmai injection combined with paclitaxel and carboplatin for advanced non-small cell lung cancer(NSCLC).Methods: Thirty-eight patients with NSCLC were randomly divided into two groups on an average,treatment group and control group.Paclitaxel(135 mg/m2) was administered to the control group by intravenous drip for three hours on the first day,carboplatin(AUC 5) was given on the first day and the twenty-first day for a cycle.While the same method to the treatment group and the patients received Shengmai injection(60 ml) containing 50 g/L GS 500 ml once daily for 15 days after chemotherapy.The efficiency was evaluated according to the current efficiency evaluation standard for solid tumor formulated by WHO after two-cycle treatment.Results: The current efficiency rate in the two groups was 52.6% and 47.4% respectively.The Karnorfsky scores for 6 patients increased in treatment group,while 3 in control group.The patients in treatment group gained more weight.The incidence rate of myelosuppression in treatment group was much lower.Conclusion: Shengmai injection can effectively improve living quality of patients,and reduce myelosuppression after chemotherapy.